[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629606":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":35,"responsibleParty":175,"collaborators":177,"id":181,"slug":182,"hasResults":183,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":183,"sex":189,"minAge":190,"maxAge":18,"enrollmentInfo":191,"targetDuration":18,"studyType":194,"phases":195,"briefSummary":197,"conditions":198,"keywords":202,"overallStatus":38,"whyStopped":18,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":226},{"fullName":5,"class":6},"Fundación para la Investigación del Hospital Clínico de Valencia","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention arm","EXPERIMENTAL","Intravenous iron administered according to protocol and SmPC.",[13],"Drug: Ferric Carboxymaltose Injection [Ferinject]",{"label":15,"type":16,"description":17,"interventionNames":18},"Control arm","NO_INTERVENTION","No specific intervention for iron deficiency (standard of care post-acute coronary syndrome)",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Ferric Carboxymaltose Injection [Ferinject]","Intervention Description (Treatment Arm)\n\nSingle intravenous administration of ferric carboxymaltose (Ferinject®) given at baseline within 15 days after the index acute coronary syndrome. The total iron dose is individually calculated according to body weight and hemoglobin levels, in accordance with the approved Summary of Product Characteristics (maximum 15 mg\u002Fkg, not exceeding 2,000 mg). The drug is administered in a monitored hospital setting. No additional iron doses are planned during follow-up.\n\nIntervention Description (Control Arm)\n\nStandard post-acute coronary syndrome care without specific treatment for iron deficiency. No intravenous or oral iron supplementation is administered per protocol.",[9],[26,31],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"Clara Bonanad Lozano, Doctor","CONTACT","+34 686 10 70 71","clarabonanad@gmail.com",{"name":32,"role":28,"phone":33,"phoneExt":18,"email":34},"Claudio Rivadulla Varela, Doctor","+34 625 11 46 86","c.rivare@hotmail.com",[36,57,73,88,103,118,133,147,161],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Hospital Clínico Universitario Virgen de la Arrixaca","RECRUITING","El Palmar","Murcia","30120","Spain","ES",{"type":45,"coordinates":46},"Point",[47,48],-1.16095,37.93939,{"lat":48,"lon":47},[51,55],{"name":52,"role":28,"phone":53,"phoneExt":18,"email":54},"María Asunción Esteve Pastor, Doctor","+34968381027","masunep@gmail.com",{"name":52,"role":56,"phone":18,"phoneExt":18,"email":18},"PRINCIPAL_INVESTIGATOR",{"facility":58,"status":59,"city":60,"state":61,"zip":18,"country":42,"countryCode":43,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Hospital Álvaro Cunqueiro","NOT_YET_RECRUITING","Vigo","Pontevedra",{"type":45,"coordinates":63},[64,65],-8.72264,42.23282,{"lat":65,"lon":64},[68,72],{"name":69,"role":28,"phone":70,"phoneExt":18,"email":71},"Sergio Raposeiras Roubin, Doctor","+34886209106","raposeiras26@hotmail.com",{"name":69,"role":56,"phone":18,"phoneExt":18,"email":18},{"facility":74,"status":38,"city":75,"state":18,"zip":76,"country":42,"countryCode":43,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Hospital Universitario de Badajoz","Badajoz","06080",{"type":45,"coordinates":78},[79,80],-6.97061,38.87789,{"lat":80,"lon":79},[83,87],{"name":84,"role":28,"phone":85,"phoneExt":18,"email":86},"Javier Pérez Cervera, Doctor","+34637998882","jperezcervera@gmail.com",{"name":84,"role":56,"phone":18,"phoneExt":18,"email":18},{"facility":89,"status":59,"city":90,"state":18,"zip":91,"country":42,"countryCode":43,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Hospital Clínic de Barcelona","Barcelona","08036",{"type":45,"coordinates":93},[94,95],2.15899,41.38879,{"lat":95,"lon":94},[98,102],{"name":99,"role":28,"phone":100,"phoneExt":18,"email":101},"Pedro Luis Cepas Guillén, Doctor","+34662038836","CEPAS@clinic.cat",{"name":99,"role":56,"phone":18,"phoneExt":18,"email":18},{"facility":104,"status":38,"city":105,"state":18,"zip":106,"country":42,"countryCode":43,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"Hospital Universitario Clínico San Cecilio","Granada","18016",{"type":45,"coordinates":108},[109,110],-3.60667,37.18817,{"lat":110,"lon":109},[113,117],{"name":114,"role":28,"phone":115,"phoneExt":18,"email":116},"Diego Segura-Rodríguez, Doctor","+34958023000","diegoseguracardio@gmail.com",{"name":114,"role":56,"phone":18,"phoneExt":18,"email":18},{"facility":119,"status":59,"city":120,"state":18,"zip":121,"country":42,"countryCode":43,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"Hospital Universitario de León","León","24071",{"type":45,"coordinates":123},[124,125],-5.57032,42.60003,{"lat":125,"lon":124},[128,132],{"name":129,"role":28,"phone":130,"phoneExt":18,"email":131},"Maria Thiscal López Lluva, Doctor","+34 652 684 953","mtl.lluva@gmail.com",{"name":129,"role":56,"phone":18,"phoneExt":18,"email":18},{"facility":134,"status":38,"city":135,"state":18,"zip":136,"country":42,"countryCode":43,"cosmosGeoPoint":137,"geoPoint":141,"contacts":142},"Hospital Clínico San Carlos","Madrid","28040",{"type":45,"coordinates":138},[139,140],-3.70256,40.4165,{"lat":140,"lon":139},[143],{"name":144,"role":28,"phone":145,"phoneExt":18,"email":146},"David Vivas Balcones, Doctor","+34658477955","dvivas@secardiologia.es",{"facility":148,"status":59,"city":149,"state":18,"zip":150,"country":42,"countryCode":43,"cosmosGeoPoint":151,"geoPoint":155,"contacts":156},"Hospital Universitario de Navarra","Pamplona","31008",{"type":45,"coordinates":152},[153,154],-1.64323,42.81687,{"lat":154,"lon":153},[157,160],{"name":158,"role":28,"phone":18,"phoneExt":18,"email":159},"Gonzalo Luis Alonso Salinas, Doctor","gonzalol.alonso@gmail.com",{"name":158,"role":56,"phone":18,"phoneExt":18,"email":18},{"facility":162,"status":38,"city":163,"state":18,"zip":164,"country":42,"countryCode":43,"cosmosGeoPoint":165,"geoPoint":169,"contacts":170},"Hospital Clínico Universitario de Valencia","Valencia","46010",{"type":45,"coordinates":166},[167,168],-0.37966,39.47391,{"lat":168,"lon":167},[171,172,173],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},{"name":27,"role":56,"phone":18,"phoneExt":18,"email":18},{"name":32,"role":174,"phone":18,"phoneExt":18,"email":18},"SUB_INVESTIGATOR",{"type":176,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[178],{"name":179,"class":180},"AstraZeneca","INDUSTRY","100629606","phase-4-effect-of-intravenous-iron-on-quality-of-life-in-older-patients-with-acute-coronary-syndrome-100629606",false,"NCT07476859","Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome","Phase IV, Open-label, Randomized Clinical Trial on the Effect of Intravenous Iron on Quality of Life in Elderly Patients With Acute Coronary Syndrome","HI-COR-65","Inclusion Criteria:\n\n1. Age ≥ 65 years.\n2. Hospitalization for confirmed acute coronary syndrome (ACS) within 15 days prior to enrollment.\n3. Iron deficiency diagnosed at admission or within 15 days after the index ACS event, defined as:\n\n   * Serum ferritin \\\u003C 100 ng\u002FmL, OR\n   * Transferrin saturation (TSAT) \\\u003C 20%.\n4. Ability to provide written informed consent prior to participation.\n\nExclusion Criteria:\n\n1. Active malignancy.\n2. End-stage or terminal illness as determined by the IDC-Pal score.\n3. Known heart failure with left ventricular ejection fraction (LVEF) \\\u003C 40% prior to enrollment, or development of LVEF \\\u003C 40% during hospitalization or within 15 days after ACS.\n4. Chronic dialysis or advanced renal or hepatic failure.\n5. Severe anemia (hemoglobin \\\u003C 10 g\u002FdL) at the time of ACS or within 15 days after the event.\n6. Prior treatment with intravenous or oral iron within 12 months before the index ACS.\n7. Known hypersensitivity to ferric carboxymaltose, other parenteral iron products, or any component of the formulation.\n8. Evidence of iron overload or disorders of iron metabolism.\n9. Ongoing bacteremia or active systemic infection.\n10. Participation in another interventional clinical trial involving an investigational medicinal product.\n11. Any condition that, in the investigator's opinion, would compromise safety, protocol compliance, or study integrity.","ALL","65 Years",{"count":192,"type":193},538,"ESTIMATED","INTERVENTIONAL",[196],"PHASE4","The goal of this phase IV, open-label, randomized clinical trial is to evaluate whether intravenous iron improves quality of life in adults aged 65 years and older with iron deficiency after an acute coronary syndrome (ACS).\n\nThe main questions it aims to answer are:\n\n* Does intravenous iron improve quality of life at 6 and 12 months?\n* Does it reduce frailty and adverse clinical outcomes?\n\nResearchers will compare intravenous ferric carboxymaltose with standard of care.\n\nParticipants will:\n\n* Be randomly assigned to receive intravenous iron or standard care\n* Attend three study visits over 12 months\n* Complete questionnaires and undergo blood tests",[199,200,201],"Acute Coronary Syndromes (ACS)","Iron Deficiencies","Elderly (People Aged 65 or More)",[203,204,205,206,207,208,209,210,211,212,213,214,215,216],"Acute coronary syndrome","Iron deficiency","Intravenous iron","Ferric carboxymaltose","Quality of life","Older adults","Myocardial infarction","Frailty","Cardiovascular outcomes","Biological aging","ELOVL2 methylation","Telomere length","Klotho","FGF23","2026-03-20",{"date":219,"type":220},"2026-03-24","ACTUAL",{"date":222,"type":220},"2026-03-05",{"date":224,"type":193},"2028-05",{"name":5,"class":6},9]